Indusatumab vedotin

N/A

Report date: 2024/02/05 13:59:23

Base Information

Drug NameIndusatumab vedotin
Drug Alias Name5F9vcMMAETAK-264MLN-0264
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionHeat-stable enterotoxin receptor antagonistsTubulin inhibitors
TargetsHeat-stable enterotoxin receptorTubulin
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesTaiwan +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMillennium Pharmaceuticals IncSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMillennium Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsGastroesophageal Junction NeoplasmsPancreatic NeoplasmsStomach Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipedia